Literature DB >> 2677676

Alteration of a single nucleotide allows efficient binding of H2TF1/KBF1 to the immunoglobulin kappa enhancer B motif.

F Mauxion1, R Sen.   

Abstract

NF-kappa B (a protein present constitutively only in B cells) and H2TF1/KBF1 (a more ubiquitously distributed protein[s]) are two transcription factors that recognize very similar DNA sequences. However, the binding site associated with the kappa immunoglobulin gene enhancer (kappa B) is recognized predominantly by NF-kappa B. Using synthetically altered recognition sequences, we showed that the B-cell-specific NF-kappa B-binding site in the kappa enhancer can be converted to one that binds both NF-kappa B and the ubiquitous protein(s) H2TF1/KBF1 by substitution of a single nucleotide. Furthermore, transient transfection experiments suggested that NF-kappa B and H2TF1/KBF1 are functionally different even though their DNA recognition specificities are very similar.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2677676      PMCID: PMC362404          DOI: 10.1128/mcb.9.8.3548-3552.1989

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  21 in total

1.  Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism.

Authors:  R Sen; D Baltimore
Journal:  Cell       Date:  1986-12-26       Impact factor: 41.582

2.  Protein-binding sites in Ig gene enhancers determine transcriptional activity and inducibility.

Authors:  M Lenardo; J W Pierce; D Baltimore
Journal:  Science       Date:  1987-06-19       Impact factor: 47.728

3.  Multiple nuclear factors interact with the immunoglobulin enhancer sequences.

Authors:  R Sen; D Baltimore
Journal:  Cell       Date:  1986-08-29       Impact factor: 41.582

4.  Two transcription factors, NF-kappa B and H2TF1, interact with a single regulatory sequence in the class I major histocompatibility complex promoter.

Authors:  A S Baldwin; P A Sharp
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

5.  A common positive trans-acting factor binds to enhancer sequences in the promoters of mouse H-2 and beta 2-microglobulin genes.

Authors:  A Israël; A Kimura; M Kieran; O Yano; J Kanellopoulos; O Le Bail; P Kourilsky
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

6.  Binding of a nuclear factor to a regulatory sequence in the promoter of the mouse H-2Kb class I major histocompatibility gene.

Authors:  A S Baldwin; P A Sharp
Journal:  Mol Cell Biol       Date:  1987-01       Impact factor: 4.272

7.  Oligonucleotide that binds nuclear factor NF-kappa B acts as a lymphoid-specific and inducible enhancer element.

Authors:  J W Pierce; M Lenardo; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

8.  Human immunoglobulin kappa gene enhancer: chromatin structure analysis at high resolution.

Authors:  J M Gimble; E E Max
Journal:  Mol Cell Biol       Date:  1987-01       Impact factor: 4.272

9.  B-cell nuclear proteins binding in vitro to the human immunoglobulin kappa enhancer: localization by exonuclease protection.

Authors:  J M Gimble; D Levens; E E Max
Journal:  Mol Cell Biol       Date:  1987-05       Impact factor: 4.272

10.  Purification of KBF1, a common factor binding to both H-2 and beta 2-microglobulin enhancers.

Authors:  O Yano; J Kanellopoulos; M Kieran; O Le Bail; A Israël; P Kourilsky
Journal:  EMBO J       Date:  1987-11       Impact factor: 11.598

View more
  11 in total

1.  Comparison of constitutive and inducible transcriptional enhancement mediated by kappa B-related sequences: modulation of activity in B cells by human T-cell leukemia virus type I tax gene.

Authors:  F Mauxion; C Jamieson; M Yoshida; K Arai; R Sen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

Review 2.  Tumor necrosis factor regulation of major histocompatibility complex gene expression.

Authors:  D R Johnson; J S Pober
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

3.  Multicomponent differentiation-regulated transcription factors in F9 embryonal carcinoma stem cells.

Authors:  M K Shivji; N B La Thangue
Journal:  Mol Cell Biol       Date:  1991-03       Impact factor: 4.272

4.  DNase I-hypersensitive sites and transcription factor-binding motifs within the mouse E beta meiotic recombination hot spot.

Authors:  R Shenkar; M H Shen; N Arnheim
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

5.  Regulation of the class II-associated invariant chain gene in normal and mutant B lymphocytes.

Authors:  C Doyle; P J Ford; P D Ponath; T Spies; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

6.  Two genes encode factors with NF-kappa B- and H2TF1-like DNA-binding properties.

Authors:  A K Rustgi; L J Van 't Veer; R Bernards
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

7.  Inhibition of phorbol ester-induced cellular adhesion by competitive binding of NF-kappa B in vivo.

Authors:  S L Eck; N D Perkins; D P Carr; G J Nabel
Journal:  Mol Cell Biol       Date:  1993-10       Impact factor: 4.272

8.  p105, the NF-kappa B p50 precursor protein, is one of the cellular proteins complexed with the v-Rel oncoprotein in transformed chicken spleen cells.

Authors:  A J Capobianco; D Chang; G Mosialos; T D Gilmore
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

9.  Homodimer of p50 (NF kappa B1) does not introduce a substantial directed bend into DNA according to three different experimental assays.

Authors:  D V Kuprash; N R Rice; S A Nedospasov
Journal:  Nucleic Acids Res       Date:  1995-02-11       Impact factor: 16.971

10.  Changes in NF-kappa B and ISGF3 DNA binding activities are responsible for differences in MHC and beta-IFN gene expression in Ad5- versus Ad12-transformed cells.

Authors:  U Nielsch; S G Zimmer; L E Babiss
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.